Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 46.0 Dacogen (decitabine)
Dacogen (decitabine) is an antineoplastic analog of 2-deoxycytidine; approved by the FDA for treatment of myelodysplastic syndrome.
MBP 121.0 Dalvance (dalbavancin)
Dalvance (dalbavancin), a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking.
MBP 139.0 Darzalex (daratumumab)
Darzalex (daratumumab) is an IgG1Κ human monoclonal antibody directed against CD38. Darzalex is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.